LUGPA 2025 CME Enduring Program: Operationalizing the Science -Translating New Concepts into Clinical Practice-2025 CME Program Part 5

Video Transcription

Video Summary

Dr. Martin Miner from Brown University discussed testosterone therapy controversies and findings from the TRAVERSE 2025 study. Hypogonadism prevalence varies, with most cases related to metabolic conditions like obesity and diabetes, often classified as age-related or functional hypogonadism. Historically, FDA approval limited testosterone therapy to men with classical hypogonadism causes, excluding age-related cases. Recent FDA label changes now allow therapy for broader populations following the TRAVERSE cardiovascular study, which showed no increased major cardiovascular event risk for men with testosterone deficiency, including high-risk patients. The study also found improvements in libido and depression but no significant erectile function gains and no increased prostate cancer risk. Unexpectedly, fracture rates were higher in the testosterone group, likely related to increased activity, not treatment. Additionally, the T4DM study suggested testosterone therapy might aid type 2 diabetes regression by enhancing insulin sensitivity. Overall, testosterone therapy presents low cardiovascular risk and may improve certain health parameters in hypogonadal men.

Keywords

Testosterone therapy

Hypogonadism

TRAVERSE 2025 study

Cardiovascular risk

Metabolic conditions

Type 2 diabetes regression